Kala Pharmaceuticals Inc. (KALA)
6.91
-0.01 (-0.14%)
At close: Mar 24, 2025, 3:59 PM
6.79
-1.73%
After-hours: Mar 24, 2025, 07:56 PM EDT
-0.14% (1D)
| Bid | 6.53 |
| Market Cap | 42.09M |
| Revenue (ttm) | 92.14K |
| Net Income (ttm) | -51.29M |
| EPS (ttm) | -11.67 |
| PE Ratio (ttm) | -0.59 |
| Forward PE | -1.46 |
| Analyst | Buy |
| Ask | 7.05 |
| Volume | 14,847 |
| Avg. Volume (20D) | 61,998 |
| Open | 6.85 |
| Previous Close | 6.92 |
| Day's Range | 6.52 - 7.07 |
| 52-Week Range | 4.21 - 11.20 |
| Beta | -2.20 |
About KALA
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye ...
Sector Healthcare
IPO Date Jul 20, 2017
Employees 43
Stock Exchange NASDAQ
Ticker Symbol KALA
Website https://www.kalarx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for KALA stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 117.08% from the latest price.
Stock Forecasts1 month ago
-31.62%
KALA BIO shares are trading lower after the compan...
Unlock content with
Pro Subscription
9 months ago
+40.22%
KALA BIO shares are trading higher. The company announced a $12.5 million private placement.
